Announcements Trials
Browse Landscape

Status

No longer available 3Approved for marketing 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 82Observational 8Expanded_access 4

Sponsor

Cancer Type

Other hematologic neoplasm 5Myeloid 4Lymphoid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Blast Crisis 2Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1

Interventions

nilotinib 4ruxolitinib 2ponatinib 2venetoclax 1selinexor 1navitoclax 1midostaurin 1fludarabine phosphate 1asciminib 1Whole-Body Irradiation 1Transplantation 1Tacrolimus 1Mycophenolic Acid 1Imatinib Mesylate 1Dasatinib 1Cytarabine 1Cord Blood Stem Cell Transplantation 1Busulfan 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Expanded_access × nilotinib × Myeloid × Clear all
NCT04518644 2023-04-28

Nilotinib, for Patients With CML-CP or CML-AP

Novartis

No longer available
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00905593 2012-07-18

ENACT

Novartis

Approved for marketing
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00302016 2011-08-26

Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

Novartis

No longer available
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00413270 2011-07-13

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Novartis

No longer available
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡